Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
#3320 TGF-β increase caspase activation and migration in typical bronchial carcinoids
Introduction: Typical bronchial carcinoids (TBC) are well-differentiated neuroendocrine neoplasms (NEN) whose management can still be very challenging due to reduced sensitivity to therapy. Previous studies have reported TGF-β’s ability to activate mTOR pathway and induce epithelial to mesenchymal transition (EMT). Moreover, preliminary results show an overexpression of TGF-β signalling and caspase activation in TBC.
Conference: 18th Annual ENETS Concerence (2021)
Presenting Author: Gagliardi I
Authors: Borges de Souza P, Gagliardi I, Martelli M, Zatelli M,
Keywords: bronchial carcinoid, TGF-β signalling, mTOR, EMT,
#2983 Differential TGF-β Signalling in Typical and Atypical Bronchial Carcinoids
Introduction: Typical and atypical bronchial carcinoids (TBC and ABC) are well-differentiated neuroendocrine neoplasms (NEN). Metastatic BC having low to moderate mitotic count may still be treated with somatostatin analogues and mTOR inhibitors; however, TBC and ABC have been reported to respond very differently to therapy and an effective treatment algorithm is still lacking. TGF-β is known for its ability to activate mTOR pathway and induce epithelial mesenchymal transition, affecting cell pathophysiological capabilities such as proliferation, migration and tissue invasiveness.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Borges de Souza P
Authors: Borges de Souza P, Tagliatti V, Capobianco S, Ambrosio M, Chinnici S,
Keywords: Neuroendocrine neoplasms, bronchial carcinoids, TGF-β,
Introduction: In patients with bronchopulmonary or gastroenteropancreatic neuroendocrine neoplasms (NEN) the mTOR inhibitor everolimus may prolong progression-free survival (PFS). However, this is countered by potentially significant toxicity.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Wetz C, Genseke P, Schatka I, Jann H, Rogasch J,
Keywords: Neuroendocrine Neoplasia, Asphericity, Everolimus, Prediction,
#2910 Virotherapy Shows Promising Efficacy in Neuroendocrine Cancers
Introduction: So far, there have been only two clinical studies using virotherapeutics to treat neuroendocrine cancers (NCT00314925 & NCT02749331). Notably, none of these approaches employed a clinically approved virotherapeutic compound.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Lauer U
Authors: Lauer U, Berchtold S, Smirnow I, Schaller M, Fehrenbacher B,
Keywords: neuroendocrine, cancer, virotherapy, virotherapeutics, preclinical, research,
Introduction: Everolimus (EVE) (mTOR inhibitor) is an effective drug in the treatment of well-differentiated NETs of different localizations, however, prognostic factors for the correct choice of therapy are not well understood.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Markovich A, Kuznetsova A, Gorbunova V, Orel N, Emelianova G,
Keywords: neuroendocrine tumors, everolimus, uni- and multivariate analysis,